DGAP-News

Vita 34 AG acquires MK Beleggingsmaatschappij Venlo B.V. as a new strategic investor and secures support for further corporate action

DGAP-News: Vita 34 AG / Key word(s): Investment Vita 34 AG acquires MK Beleggingsmaatschappij Venlo B.V. as a new strategic investor and secures support for further corporate action 14.06.2017 / 19:28 The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION, PUBLICATION OR DISCLOSURE IN OR WITHIN THE US, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION IS UNLAWFUL. PLEASE NOTE THE IMPORTANT NOTICES AT THE END OF THIS COMMUNICATION.

Vita 34 AG acquires MK Beleggingsmaatschappij Venlo B.V. as a new strategic investor and secures support for further corporate action

- Through MK Beleggingsmaatschappij Venlo B.V., Mr. Köhler takes over newly issued shares of up to 10% of the share capital

- Additional backstop agreed for just under EUR 3 million in connection with the upcoming rights issue

Leipzig, June 14, 2017 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), Europe's second largest stem cell database, today announced the acquisition of a new strategic investor. Following the capital increase adopted yesterday, MK Beleggingsmaatschappij Venlo B.V., the Netherlands (MKBV), will hold approx. 9.1% of the share capital of Vita 34 and has also agreed to support Vita 34 in implementing its planned rights issue. To ensure the success of this rights issue, MKBV has assumed a backstop obligation according to which it will take over any unsubscribed new shares under this planned rights issue up to a maximum amount of just under EUR 3 million, provided the issue price does not exceed EUR 6.50. On April 20, 2017, Vita 34 AG had announced its plans to implement a capital increase including preemptive rights of existing shareholders to generate proceeds of up to EUR 5 million.

MKBV is the investment entity of Michael Köhler, CEO SHOP APOTHEKE Europe N.V., Venlo, Netherlands. Michael Köhler has more than 20 years experience in the pharmaceutical industry, including posts at Hoechst and Aventis. His investments focus on equity interests in medical technology and pharmaceutical companies. The investment in Vita 34 reflects the strategic potential shown by the stem cell therapy segment.